Generic Tivorbex Availability
Last updated on Sep 11, 2024.
Tivorbex is a brand name of indomethacin, approved by the FDA in the following formulation(s):
TIVORBEX (indomethacin - capsule;oral)
-
Manufacturer: GENUS
Approval date: February 24, 2014
Strength(s): 20MG (discontinued) [RLD], 40MG (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tivorbex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Formulation of indomethacin
Patent 8,734,847
Issued: May 27, 2014
Inventor(s): Dodd Aaron & Meiser Felix & Norret Marck & Russell Adrian & Bosch H William
Assignee(s): Iceutica Py Ltd.The present invention relates to methods for producing particles of indomethacin using dry milling processes as well as compositions comprising indomethacin, medicaments produced using indomethacin in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of indomethacin administered by way of said medicaments.
Patent expiration dates:
- April 23, 2030✓
- April 23, 2030
-
Formulation of indomethacin
Patent 8,992,982
Issued: March 31, 2015
Inventor(s): Dodd Aaron & Meiser Felix & Norret Marck & Russell Adrian & Bosch H. William
Assignee(s): Iceutica Pty Ltd.The present invention relates to methods for producing particles of indomethacin using dry milling processes as well as compositions comprising indomethacin, medicaments produced using indomethacin in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of indomethacin administered by way of said medicaments.
Patent expiration dates:
- April 23, 2030✓
- April 23, 2030
-
Formulation of indomethacin
Patent 9,089,471
Issued: July 28, 2015
Inventor(s): Dodd Aaron & Meiser Felix & Norret Marck & Russell Adrian & Bosch H. William
Assignee(s): iCeutica Pty Ltd.The present invention relates to methods for producing particles of indomethacin using dry milling processes as well as compositions comprising indomethacin, medicaments produced using indomethacin in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of indomethacin administered by way of said medicaments.
Patent expiration dates:
- April 23, 2030✓
- April 23, 2030
More about Tivorbex (indomethacin)
- Tivorbex consumer information
- Check interactions
- Compare alternatives
- Reviews (1)
- Drug images
- Latest FDA alerts (6)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: Nonsteroidal anti-inflammatory drugs
- Breastfeeding
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.